Arsanis Inc. (ASNS) Prices 4M Share IPO at $10/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Arsanis Announces Pricing of Initial Public Offering
November 15, 2017 11:20 PM ESTWALTHAM, Mass. and VIENNA, Austria, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $10.00 per share. The gross proceeds to Arsanis from the offering are expected to be $40.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Arsanis has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock from Arsanis at the public offering... More
